TY - JOUR
T1 - Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer
AU - Iyengar, Neil M.
AU - Zhou, Xi Kathy
AU - Gucalp, Ayca
AU - Morris, Patrick G.
AU - Howe, Louise R.
AU - Giri, Dilip D.
AU - Morrow, Monica
AU - Wang, Hanhan
AU - Pollak, Michael
AU - Jones, Lee W.
AU - Hudis, Clifford A.
AU - Dannenberg, Andrew J.
N1 - Funding Information:
This work was supported by grants and contracts NIH/NCI HHSN2612012000181 and NIH/NCI R01CA154481 (to A.J. Dannenberg), UL1TR000457 of the Clinical and Translational Science Center at Weill Cornell Medical College (to N.M. Iyengar and X. K. Zhou), 2013 Conquer Cancer Foundation of the ASCO Young Investigator Award (to N.M. Iyengar), the Botwinick-Wolfensohn Foundation (in memory of Mr. and Mrs. Benjamin Botwinick; to A.J. Dannenberg), MSKCC Center for Metastasis Research (to C.A. Hudis), the Breast Cancer Research Foundation (to A.J. Dannenberg and C.A. Hudis), and Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). L.W. Jones is supported by grants from the NCI.
Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Purpose: Obesity, insulin resistance, and elevated levels of circulating proinflammatory mediators are associated with poorer prognosis in early-stage breast cancer. To investigate whether white adipose tissue (WAT) inflammation represents a potential unifying mechanism, we examined the relationship between breast WAT inflammation and the metabolic syndrome and its prognostic importance. Experimental Design: WAT inflammation was defined by the presence of dead/dying adipocytes surrounded by macrophages forming crown-like structures (CLS) of the breast. Two independent groups were examined in cross-sectional (cohort 1) and retrospective (cohort 2) studies. Cohort 1 included 100 women undergoing mastectomy for breast cancer risk reduction (n = 10) or treatment (n = 90). Metabolic syndrome-associated circulating factors were compared by CLS-B status. The association between CLS of the breast and the metabolic syndrome was validated in cohort 2, which included 127 women who developed metastatic breast cancer. Distant recurrence-free survival (dRFS) was compared by CLS-B status. Results: In cohorts 1 and 2, breast WAT inflammation was detected in 52 of 100 (52%) and 52 of 127 (41%) patients, respectively. Patients with breast WAT inflammation had elevated insulin, glucose, leptin, triglycerides, C-reactive protein, and IL6 and lower high-density lipoprotein cholesterol and adiponectin (P < 0.05) in cohort 1. In cohort 2, breast WAT inflammation was associated with hyperlipidemia, hypertension, and diabetes (P < 0.05). Compared with patients without breast WAT inflammation, the adjusted HR for dRFS was 1.83 (95% CI, 1.07-3.13) for patients with inflammation. Conclusions: WAT inflammation, a clinically occult process, helps to explain the relationship between metabolic syndrome and worse breast cancer prognosis.
AB - Purpose: Obesity, insulin resistance, and elevated levels of circulating proinflammatory mediators are associated with poorer prognosis in early-stage breast cancer. To investigate whether white adipose tissue (WAT) inflammation represents a potential unifying mechanism, we examined the relationship between breast WAT inflammation and the metabolic syndrome and its prognostic importance. Experimental Design: WAT inflammation was defined by the presence of dead/dying adipocytes surrounded by macrophages forming crown-like structures (CLS) of the breast. Two independent groups were examined in cross-sectional (cohort 1) and retrospective (cohort 2) studies. Cohort 1 included 100 women undergoing mastectomy for breast cancer risk reduction (n = 10) or treatment (n = 90). Metabolic syndrome-associated circulating factors were compared by CLS-B status. The association between CLS of the breast and the metabolic syndrome was validated in cohort 2, which included 127 women who developed metastatic breast cancer. Distant recurrence-free survival (dRFS) was compared by CLS-B status. Results: In cohorts 1 and 2, breast WAT inflammation was detected in 52 of 100 (52%) and 52 of 127 (41%) patients, respectively. Patients with breast WAT inflammation had elevated insulin, glucose, leptin, triglycerides, C-reactive protein, and IL6 and lower high-density lipoprotein cholesterol and adiponectin (P < 0.05) in cohort 1. In cohort 2, breast WAT inflammation was associated with hyperlipidemia, hypertension, and diabetes (P < 0.05). Compared with patients without breast WAT inflammation, the adjusted HR for dRFS was 1.83 (95% CI, 1.07-3.13) for patients with inflammation. Conclusions: WAT inflammation, a clinically occult process, helps to explain the relationship between metabolic syndrome and worse breast cancer prognosis.
UR - http://www.scopus.com/inward/record.url?scp=84968739477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84968739477&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-2239
DO - 10.1158/1078-0432.CCR-15-2239
M3 - Article
C2 - 26712688
AN - SCOPUS:84968739477
SN - 1078-0432
VL - 22
SP - 2283
EP - 2289
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 9
ER -